美罗培南
肠杆菌科
耐碳青霉烯类肠杆菌科
碳青霉烯
微生物学
肠杆菌科感染
厄他培南
医学
生物
抗生素
抗生素耐药性
大肠杆菌
基因
生物化学
作者
Renato Pascale,Maddalena Giannella,Michele Bartoletti,Pierluigi Viale,Federico Pea
标识
DOI:10.1080/14787210.2019.1673731
摘要
Introduction: The epidemiology of carbapenem-resistant Enterobacterales (CRE) is increasingly worldwide. Production of carbapenemases is the most common and efficient mechanism of carbapenem resistance, and could theoretically be overcome by optimizing the pharmacokinetic/pharmacodynamic (PK/PD) behavior of meropenem.Areas covered: This article overviews the available literature concerning the potential role that meropenem may still have in the treatment carbapenem-resistant Enterobacteriaceae infections. Clinical studies published in English language until June 2019 were searched on PubMed database.Expert commentary: High-dose continuous infusion meropenem-based combination regimens could still represent a valuable option for treating CRE infections in specific circumstances. Knowledge of the local prevalent mechanisms of carbapenem resistance, of patient clinical severity, of the site of infection, of an accurate minimum inhibitory concentration (MIC) value, coupled with the possibility of carrying-out a real-time therapeutic drug monitoring (TDM)-based PK/PD optimization of drug exposure must all be considered as fundamental for properly pursuing this goal.
科研通智能强力驱动
Strongly Powered by AbleSci AI